Castle biosciences stock.

Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Castle Biosciences is a commercial-stage diagnostics company that provides testing services for dermatological cancers. …Jean Carruthers Faculty Owner/Co-Owner Founder/Co-Founder: Carruthers Instruments; Consulting Fee: Alastin Skincare, Allergan Aesthetics, Appiell, Avari, Evolus ...Castle Biosciences is registered under the ticker NASDAQ:CSTL . Their stock opened with $16.00 in its Jul 24, 2019 IPO. Castle Biosciences is funded by 11 investors. Spindletop Capital Management and BrightEdge Fund are the most recent investors. Castle Biosciences has acquired 3 organizations. Their most recent acquisition was AltheaDx …Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ...

Dec 4, 2023 · Castle Biosciences Price Performance. NASDAQ CSTL traded up $0.07 during trading on Monday, reaching $20.04. The company’s stock had a trading volume of 33,667 shares, compared to its average ... Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ...

52.55K (21.02% of Avg) 65 Day Avg: 250.03K Becton Dickinson & Co. Siemens Healthineers AG Qiagen N.V. Company & People Research & Ratings President, Chief Executive Officer & Director Franklin...

Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Europe PMC is an archive of life sciences journal literature. https://orcid.orgCastle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.

Mar 1, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...

Castle Biosciences stock declined 14% over a five-day trading period ending 3/10/2021, compared to a broader market (S&P500) rise of 2.3%; A change of -14% or more over five trading days is a 4% ...The latest price target for Castle Biosciences ( NASDAQ: CSTL) was reported by Keybanc on Friday, August 4, 2023. The analyst firm set a price target for …CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 820 S. Friendswood Drive, Suite 201, Friendswood, Texas 77546 (Address of principal executive offices) (Zip Code) (866) 788-9007Oct 31, 2023 · Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently down 7.52% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26. Year to ... 7 Nis 2021 ... Product details ... Do you want to earn up to a 1117163% annual return on your money by two trades per day on Castle Biosciences Inc CSTL Stock?In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.Castle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ...

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.As soon as the Novitas decision reversal decision was announced, Castle stock began to climb, jumping from ~$13 per share, to nearly $20 per share, a >50% gain that leaves Castle more or less back ...Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing DecisionDx ®-Melanoma can improve risk stratification over American Joint Committee on Cancer (AJCC) staging alone in patients with stage I cutaneous melanoma …Castle Biosciences Inc Stock Earnings The value each CSTL share was expected to gain vs. the value that each CSTL share actually gained. CSTL ( CSTL ) reported Q3 2023 earnings per share (EPS) of -$0.26 , beating estimates of -$0.76 by 66.32% .On November 2, 2023, Castle Biosciences (NASDAQ:CSTL) released its Q3 2023 financial report, showcasing impressive results. The company reported a loss of $ (0.26) per share, surpassing the analyst consensus estimate of $ (0.76) by an impressive 65.79 percent. This marks a remarkable 66.23 percent increase in losses compared to the same period ...Castle Biosciences Stock Forecast 11-20-2023. Forecast target price for 11-20-2023: $ 18.23. Negative dynamics for Castle Biosciences shares will prevail with possible volatility of 2.962%. Pessimistic target level: 17.92. Optimistic target level: 18.47.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients …Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients …Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ...Mar 1, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago. Castle Biosciences is a commercial-stage diagnostics company that provides testing services for dermatological cancers. …Which technical analysis tools can be used to analyze Castle Biosciences, Inc.? Check out various oscillators, moving averages and other technical ...Castle Biosciences announced that it has completed its acquisition of AltheaDx, Inc. ... up to an additional $75.0 million in cash and common stock will be payable in connection with the ...

Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

The estimated Net Worth of Mara G. Aspinall is at least $2.42 Million dollars as of 25 August 2022. Ms. Aspinall owns over 6,000 units of Castle Biosciences stock worth over $1,626,983 and over the last 8 years she sold CSTL stock worth over $494,800. In addition, she makes $302,714 as Independent Director at Castle Biosciences.

Nov 23, 2023 · Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend. Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. Castle Creek Biosciences: Cell and Gene Therapy Company : Castle Creek Biosciences, Inc. “ We are building a leading cell and gene therapy company for patients and families seeking relief from devastating genetic diseases. ”. Matthew Gantz, President and Chief Executive Officer. Courtesy of debra—The Dystrophic Epidermolysis Bullosa ...2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%)... Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to …11/08/2023 - 01:00 PM. FRIENDSWOOD, Texas -- (BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this …Of the 172 institutional investors that purchased Castle Biosciences stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Granahan Investment Management LLC ($1.82M), Principal Financial Group Inc. ($1.13M), Millennium Management LLC ($1.03M), Wasatch Advisors Inc. …Jul 11, 2023 · Castle Biosciences makes tests for patients diagnosed with certain diseases to help evaluate optimal treatment options. Read my analysis of CSTL stock here. ... Castle stock had fallen to ~$33 per ... In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.Castle Biosciences is the only provider of 31-GEP testing, and all testing is performed in a College of American Pathologists/Clinical Laboratory Improvement Amendments–certified laboratory. We evaluated the ability of the 31-GEP to stratify risk in MSS and overall survival (OS) to confirm the prognostic ability of the 31-GEP at the …Ms. Oelschlager CSTL stock SEC Form 4 insiders trading. Kristen has made over 4 trades of the Castle Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 7,178 units of CSTL stock worth $17,155 on 28 December 2022.. The largest trade she's ever made was selling 10,000 units of Castle …Instagram:https://instagram. aep dividendreal estate investment groupstop financial group stock predictionreal estate in tuscany Castle Biosciences Inc (CSTL) Stock Price & News - Google Finance Markets 34,932.41 -0.037% 4,509.11 +0.019% +0.87 14,101.58 -0.086% -12.09 1,795.29 +21.54 VIX 13.72 …Best Stock Of The Week Castle Biosciences Cstl Option Informants Based on 3 Wall Street analysts offering 12 month price targets for Castle Biosciences in the last 3 months. . 1 day agoSVB Securities analyst Puneet Souda maintained a Buy rating on Castle Biosciences CSTL - Research Report on November 2 and set a price target of … value of a kennedy half dollarapple newest products Castle Biosciences Today's Change (-0.50%) -$0.10 Current Price $19.78 Key Data Points Market Cap $535M Day's Range $19.62 - $19.95 52wk Range $9.26 - … i need 300 now Europe PMC is an archive of life sciences journal literature.See the latest Castle Biosciences Inc stock price (CSTL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.